Haystack oncology, developer of haystack mrd™, and trisalus life sciences collaborate in connection with the clinical development of trisalus' tlr9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

Baltimore , jan. 22, 2024 /prnewswire/ -- haystack oncology, a quest diagnostics (nyse: dgx) company and developer of best-in-class personalized mrd technology (haystack mrd™), has entered a research collaboration with trisalus life sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of trisalus' sd-101, an investigational class c toll-like receptor-9 (tlr9) agonist. sd-101 is delivered via hepatic arterial infusion or pancreatic retrograde venous infusion in their phase 1 and 1b clinical trials using their proprietary pressure-enabled drug delivery™ (pedd™) to overcome the challenges associated with intratumoral pressure for patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.
DGX Ratings Summary
DGX Quant Ranking